Back to search
FDAFDA · Food and drugs·Recall number D-0241-2026

Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03

Published December 31, 2025 · Recall initiated: December 12, 2025

Summary

FDA records drug Class II recall D-0241-2026, published December 31, 2025 and initiated December 12, 2025. Recalling firm: Merck Sharp & Dohme LLC; Status: Ongoing; Reported quantity: 3 - single dose kits; Lot: Lot #: Z014503, Exp 11/15/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter: potential presence of metal particulates in the product.

What to do

Voluntary: Firm initiated · Letter

Get an email if EMEND has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
EMEND
Manufacturer
Merck Sharp & Dohme LLC
Distributor
Nationwide in the USA
Lot
Lot #: Z014503, Exp 11/15/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03 recalled?

Yes. FDA published recall D-0241-2026 on December 31, 2025. Reported hazard: Presence of particulate matter: potential presence of metal particulates in the product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: EMEND.